Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Brimonidine Tartrate 0.025% for Ocular Hyperemia
NCT01959243Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Ocular hyperemia comparing Brimonidine Tartrate with Vehicle (2 arms). Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at Day 29. Started Feb 2014; status: completed.
02
Drugs
brimonidine
03
Conditions
Ocular hyperemia
Beyond the preview
Go deeper on NCT01959243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01959243.